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Myxovirus resistance 2 (MX2) inhibits
HIV-1 infection by interacting with the
viral capsid. Betancor et al. show that in
addition to its N-terminal domain, MX2
binds to the capsid through its GTPase
domain, therefore strengthening the
interaction. Consequently, the non-
antiviral short isoform competes with the
long isoform for capsid binding and
downmodulates viral inhibition.
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Myxovirus resistance 2 (MX2/MXB) is an interferon
(IFN)-induced HIV-1 restriction factor that inhibits
viral nuclear DNA accumulation. The amino-terminal
domain of MX2 binds the viral capsid and is essential
for inhibition. Using in vitro assembled Capsid-
Nucleocapsid (CANC) complexes as a surrogate for
the HIV-1 capsid lattice, we reveal that the GTPase
(G) domain of MX2 contains a second, independent
capsid-binding site. The importance of this interac-
tion was addressed in competition assays using the
naturally occurring non-antiviral short isoform of
MX2 that lacks the amino-terminal 25 amino acids.
Specifically, these experiments show that the G
domain enhances MX2 function, and the foreshort-
ened isoform acts as a functional suppressor of the
full-length protein in a G-domain-dependent manner.
The interaction of MX2 with its HIV-1 capsid sub-
strate is thereforemulti-faceted: there are dual points
of contact that, together with protein oligomeriza-
tion, contribute to the complexity of MX2 regulation.
INTRODUCTION
Upon viral infection, activation of the innate immune response
mobilizes an antiviral state. Central to this process is the produc-
tion of type 1 interferons (IFNs); these cytokines induce the
expression of a cascade of IFN-stimulated genes (ISGs), many
of which have direct antiviral properties (Doyle et al., 2015;
Bourke et al., 2018). As with many viruses, HIV type-1 (HIV-1)
replication is suppressed by the IFN response (reviewed by
Doyle et al., 2015). In recent years, human myxovirus resistance
2 (MX2; also called MXB) has been identified as a potent, IFN-
induced inhibitor of HIV-1 infection (Goujon et al., 2013; Kane
et al., 2013; Liu et al., 2013; Bulli et al., 2016; Dicks et al.,
2018) and herpesvirus infection, including herpes simplex vi-
ruses 1 (HSV-1) and 2 (HSV-2) (Crameri et al., 2018; Schilling
et al., 2018; Staeheli and Haller 2018). MX2 mediates a block
to HIV-1 infection after reverse transcription (the synthesis of
viral cDNA), but prior or together with the integration of viralCell Repor
This is an open access article undDNA into host chromosomal DNA (Goujon et al., 2013; Kane
et al., 2013; Liu et al., 2013; Matreyek et al., 2014).
Early studies showed that the HIV-1 Capsid (CA) protein is
the virus-encoded determinant of MX2 sensitivity, since point
mutations in CA can yield MX2-insensitive viruses (Goujon
et al., 2013; Kane et al., 2013; Liu et al., 2013; Busnadiego
et al., 2014; Matreyek et al., 2014; Bulli et al., 2016). Notably,
such mutations may be located on different interfaces of the
viral CA, as illustrated by the cyclophilin A (CYPA)-binding loop
mutations P90A or G89V, and the hexamer trimeric-interface
mutations G208R or T210K, thereby implying a complicated
interplay between the CA and MX2. It has also been demon-
strated that MX2 and the CA can interact in vitro using assem-
blies of the CA and CA-Nucleocapsid (CANC) as surrogates for
theHIV-1 capsid lattice (Fribourgh et al., 2014; Fricke et al., 2014)
Because of the presence of an alternative start codon at
position 26, human MX2 is expressed as two different isoforms
of 78 and 76 kDa. Early work established that only the full-length
form of MX2 is antiviral, while the short isoform has no observ-
able anti-HIV-1 activity (Goujon et al., 2014; Matreyek et al.,
2014), a feature shared in the inhibition of herpesviruses
(Crameri et al., 2018; Schilling et al., 2018). Accordingly, it was
proposed that only the long isoform can interact with CA (Fricke
et al., 2014), with additional studies suggesting a dependence on
the arginine residues at positions 11–13 within the amino-termi-
nal domain (NTD) (Fricke et al., 2014; Schulte et al., 2015). Addi-
tionally, it has been shown that a chimeric dimer consisting of
maltose-binding protein bearing the amino-terminal 35 residues
of MX2 binds to CA assemblies, specifically at the CA tri-hex-
amer interface (Smaga et al., 2018). However, earlier work by Fri-
bourgh et al. (2014) also showed that a truncated form of MX2
lacking the amino-terminal 84 residues may still interact with
CA assemblies, albeit with lower affinity. Another unresolved
aspect of MX2’s mechanism of action concerns the extent of
oligomerization needed for viral inhibition, since some studies
have found that MX2 dimerization is sufficient (Buffone et al.,
2015; Dicks et al., 2015), whereas another analysis proposed
that higher-order oligomers might be important (Alvarez et al.,
2017).
Human MX2 belongs to the dynamin-like GTPase family,
which also includes the related protein MX1 (also called MXA).
MX1 has been acknowledged as an antiviral ISG for many years
(reviewed by Verhelst et al., 2013) and can act on a broadts 29, 1923–1933, November 12, 2019 ª 2019 The Author(s). 1923
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Binding of MX2 and Chimeric Pro-
teins to HIV-1 CANC Nanotubes
(A) 293T cells were transfected with vectors ex-
pressing human MX2, human MX1, GFP, or human
CPSF6. Cell lysates were then incubated in the
presence or absence of in vitro assembled CANC
complexes and subjected to centrifugation through
a sucrose cushion. Resulting supernatant (Sup) and
pellet fractions, together with the input sample,
were analyzed by immunoblot (n R 20). A repre-
sentative immunoblot for CANC (a-CA) is shown.
(B) CANC complexes were incubated with lysates
fromU87-MGCD4/CXCR4 cells treated with 500 U/
ml of IFNa and pelleted through a sucrose cushion.
Input, Sup, and pellet fractions were analyzed by
immunoblot (n = 4).
(C) Chimeric MX1 or GFP proteins containing the
N-terminal domain of MX2 were expressed in 293T
cells. Cell lysates were incubated with CANC
complexes, pelleted through a sucrose cushion,
and input, Sup, and pellet fractions were analyzed
by immunoblot. A representative immunoblot for
CANC (a-CA) is shown (n = 5).
(D) Deletions of residues 1–25 were introduced into
MX2, MX1 (NTDMX2), or GFP (NTDMX2), as well as
deletion of residues 1–91 from MX2. 293T cell ly-
sates expressing these proteins were mixed with
CANC assemblies, pelleted through a sucrose
cushion, and input, Sup, and pellet fractions were
analyzed by immunoblot (n R 4). A representative
immunoblot for CANC (a-CA) is shown.
(E) The triple-arginine mutation R11-13A was
introduced into MX2 and GFP (NTDMX2). Lysates
from transfected 293T cells expressing these pro-
teins were mixed with CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and pellet fractions were analyzed by immunoblot (n = 5). A
representative immunoblot for CANC (a-CA) is shown.spectrum of viruses, including influenza A virus (IAV), hepatitis B
virus (HBV), Thogoto virus (THOV), or measles virus (Pavlovic
et al., 1990; Frese et al., 1996; Kochs and Haller, 1999; Gordien
et al., 2001), but not HIV-1 (Goujon et al., 2013; Kane et al., 2013;
Liu et al., 2013). Like MX1, MX2 is composed of a disordered
NTD, followed by a GTPase (G) domain and a stalk (ST) domain,
connected by three hinge-like bundle signaling elements
(BSEs). While theG and ST domains ofMX1 andMX2 are notably
similar in sequence and overall structure (Gao et al., 2010, 2011;
Fribourgh et al., 2014), the NTD of MX2 is notably longer than
that of MX1 (91 versus 43 amino acids, respectively). There are
clear differences in the determinants of viral inhibition between
MX1 and MX2: (1) While MX2 prevents the nuclear accumulation
of HIV-1 cDNAs, human MX1 is thought to act at a post-tran-
scriptional level by inhibiting the nuclear export of HBV RNAs
(Gordien et al., 2001) or prior to transcription by trapping THOV
nucleocapsids in the cytoplasm (Kochs and Haller, 1999). (2) A
disordered loop in the ST domain (called L4) of MX1 is an impor-
tant determinant of virus inhibition, at least for IAV and THOV,
where an interaction with the viral nucleoprotein (NP) has
been shown (Mitchell et al., 2012), but this element is dispens-
able for MX2-mediated HIV-1 suppression (Goujon et al., 2014;
Verhelst et al., 2015). (3) For MX2, a key region necessary for
the inhibition of HIV-1 has been shown to be the NTD; for
example, a chimeric MX1 protein bearing the NTD of MX2 dis-1924 Cell Reports 29, 1923–1933, November 12, 2019plays equivalent antiviral activity to wild-type MX2 (Goujon
et al., 2014, 2015). (4) While GTPase activity is required for
MX1-mediated virus suppression, this enzymatic capability is
dispensable for HIV-1 inhibition by MX2 (Mitchell et al., 2012;
Goujon et al., 2013; Kane et al., 2013; Matreyek et al., 2014).
However, GTP hydrolysis may be involved in the organization
ofMX2 oligomerization (Alvarez et al., 2017), andGTPase activity
is required for the inhibition of herpesvirus infections (Crameri
et al., 2018; Schilling et al., 2018).
Here, we investigate in depth the requirements for the inter-
action betweenMX2 and the HIV-1 capsid.We show that in addi-
tion to the previously described NTD binding site, the G domain
of MX2 encodes a second, independent capsid-binding site.
Importantly, this site not only contributes to the antiviral activity
of full-length MX2, but it also enables the short MX2 isoform to
act as a negative regulator of the full-length protein.
RESULTS
MX2 Binds Assembled HIV-1 CANC Complexes
The HIV-1 capsid lattice that forms the distinctive conical core
of viral particles is composed of hexameric and pentameric
assemblies of the viral CA protein. One well-established
experimental model for studying the capsid lattice entails the
use of CANC nanotubes that are assembled in vitro using
Table 1. Summary of MX1/MX2 Chimeric Protein Binding to CANC Complexespurified recombinant protein (Campbell and Vogt, 1995; Gross
et al., 1997). These have been employed extensively for high-res-
olution structural studies (Bharat et al., 2012; Dick et al., 2018)
and for analyzing interactions between the capsid lattice and
cellular proteins (Valle-Casuso et al., 2012; Li and Sodroski,
2008; Black and Aiken, 2010; Dharan et al., 2017; Schaller
et al., 2017).
It has previously been reported that human MX2 interacts with
HIV-1 CANC complexes (Fribourgh et al., 2014; Fricke et al.,
2014). We first confirmed this observation using extracts of
transfected 293T cells expressing MX1 or MX2, as well as a
known CA-binding protein (cleavage and polyadenylation
specificity factor subunit 6 [CPSF6]; Price et al., 2012) and an
unrelated negative control protein (green fluorescent protein,
GFP), all bearing a FLAG-tag. Cell lysates were incubated with
assembled CANC complexes, subjected to centrifugation
through a sucrose cushion such that only very-high-molecular-
weight CANC complexes together with interacting factors were
pelleted, and then analyzed by immunoblotting.
As expected, CPSF6 was readily detected in the pellet frac-
tion when CANC complexes were present, but not when they
were absent, and GFP failed to interact with these complexes
(Figure 1A). As previously shown (Fricke et al., 2014), MX2
was also able to bind to CANC complexes, while the related
MX1 protein was not, again illustrating the specificity of thisinteraction (Figure 1A). Further confirmation of this finding was
obtained using lysates from IFNa-treated U87-MG CD4/
CXCR4 cells, where both the long and short isoforms of endog-
enous IFNa-induced MX2 were shown to interact with CANC
complexes, but endogenous MX1 did not (Figure 1B) (Fricke
et al., 2014).
The NTD of MX2 Is Not Solely Responsible for the
Interaction with the HIV-1 Capsid Lattice
Previous studies have proposed that the NTD of MX2 is entirely
responsible for capsid binding (Fricke et al., 2014; Schulte et al.,
2015), though other analyses have indicated that this region may
not be absolutely required (Fribourgh et al., 2014). To explore the
capsid-binding determinants of MX2 in further detail, we deter-
mined the CANC binding phenotypes for a series of GFP/MX2
and MX1/MX2 chimeric proteins, as well as MX2 deletion and
point mutants. We first transferred the NTD of MX2 to MX1
and GFP, with the resulting chimeric proteins (MX1 [NTDMX2]
and GFP [NTDMX2]) naturally expressing corresponding long
and short isoforms (Figure 1C) due to the alternative start codon
at position 26. As noted before, MX1 carrying the MX2 NTD ac-
quired the ability to bind to CANCs (Fricke et al., 2014), an obser-
vation recapitulatedwith the chimeric GFP (NTDMX2) protein (Fig-
ure 1C); importantly, only the chimera corresponding to the long
isoform of MX2 bound to CANC assemblies, with the chimeraCell Reports 29, 1923–1933, November 12, 2019 1925
Figure 2. MX2 Is Able to Bind to CANC Complexes through Its G
Domain
(A) NTD, ST, and/or G domains of MX1were introduced into the truncated form
of MX2 lacking the NTD (MX2 DNTD). 293T cell lysates expressing these
proteins were mixed with CANC assemblies, pelleted through a sucrose
cushion, and input, Sup, and pellet fractions were analyzed by immunoblot
(n = 5). A representative immunoblot for CANC (a-CA) is shown.
(B) NTD truncated MX1 (MX1 DNTD) with or without the G domain of MX2, or a
chimeric protein comprising GFP and the G domain of MX2 were expressed in
293T cells. Cell lysates were mixed with CANC assemblies, pelleted through a
sucrose cushion, and input, Sup, and pellet fractions were analyzed by
immunoblot. A representative immunoblot for CANC (a-CA) is shown (nR 3).corresponding to the short isoform that lacks the amino-terminal
25 residues (GFP [NTDMX2 D1-25]) failing to interact (Figure 1C).
Next, focusing on the NTD, we found that the deletion of the
amino-terminal 25 amino acids from the GFP (NTDMX2) and
MX1 (NTDMX2) chimeric proteins (i.e., proteins that correspond
to short isoforms expressed from the downstream codon)
abolished the ability of the NTD to interact with CANC complexes
(Figure 1D). Critically, however, we found that the short isoform
of MX2 (MX2 D1-25) was still able to bind to CANC complexes
(Figure 1D), consistent with previous results using recombinant
MX2 that lacked the first 84 residues (Fribourgh et al., 2014).
This suggested that MX2 contains capsid-binding determinants
that reside beyond the amino-terminal 84 amino acids; this was
reinforced by the finding that a truncated form ofMX2 lacking the
entire NTD (MX2 D1-91; hereafter called MX2 DNTD) also inter-
acted with CANC complexes (Figure 1D). Residues 11–13 of
the NTD of MX2 have been shown to be important for both viral
inhibition (Goujon et al., 2015) and CANC complex binding
(Schulte et al., 2015; Smaga et al., 2018). While substitution of
these three arginines for alanine abrogated the interaction be-
tween GFP (NTDMX2) and CANC complexes, the effect on the1926 Cell Reports 29, 1923–1933, November 12, 2019binding of full-length MX2 was modest (Figure 1E). Taken
together, these data confirm the important role played by the tri-
ple-arginine motif of the NTD in CA binding and highlight the
importance of the additional, independent region(s) of MX2 for
interacting with the HIV-1 capsid.
The G Domain of MX2 Interacts with the HIV-1 Capsid
To map the additional region(s) of MX2 that can bind the capsid
lattice, we created a library of MX1/MX2 chimeras where
different protein domains were swapped and binding to CANC
complexes was assessed (Table 1). One unexpected compli-
cation in these experiments was that the NTD of MX1 appeared
to have an inhibitory role on the ability of MX2 to bind to CANCs
(Table 1; Figure 2A). Accordingly, all chimeric proteins where
MX1 domains were introduced into MX2 were configured not
to contain an NTD. We found that exchanging the MX2 G
domain either alone or with the ST domain for corresponding
regions of MX1 abrogated CANC complex binding (Figure 2A).
Importantly, a reverse chimera comprising MX1 DNTD bearing
the G domain of MX2 clearly interacted with CANC assemblies,
whereas MX1 DNTD did not (Figure 2B). Finally, by showing that
a fusion of the MX2 G domain to GFP, GFP (GMX2), also bound to
CANCs (albeit relatively modestly), we confirmed that the G
domain of MX2 contains a second capsid-binding site
(Figure 2B).
The Short Isoform of MX2 (MX2 D1-25) Negatively
Regulates Wild-Type MX2 Function
Having demonstrated that the short isoform of MX2, which lacks
antiviral activity by itself (Goujon et al., 2014; Matreyek et al.,
2014), is able to bind to the HIV-1 capsid lattice (Figure 1D), we
next asked whether it might play a role in modulating the antiviral
function of full-length MX2. Since both isoforms of MX2 are IFN
inducible, we tested the ability of the short isoform to inhibit
HIV-1 infection when ectopically expressed in the absence of
IFNa or in its presence (i.e., when both endogenous isoforms
are expressed). As controls, we also ectopically expressed
wild-type MX2 (i.e., both isoforms) or an irrelevant protein (lucif-
erase; negative control).
In luciferase-expressing cells, the addition of IFNa yielded
the expected drop (16-fold) in viral infection (Figure 3A). As a
positive control, overexpression of MX2 severely reduced viral
infectivity in both the presence and the absence of IFNa
compared to the luciferase-expressing cells. As previously es-
tablished, expression of the short isoform of MX2 alone had no
effect on the efficiency of infection. In contrast, however, this
protein significantly diminished the inhibitory effect of IFNa:
6-fold inhibition, compared to 16-fold for the luciferase con-
trol (Figure 3A). Critically, this result suggests that the short iso-
form of MX2 can counteract the IFN-induced suppression of
HIV-1, with one natural possibility being that it interferes with
the activity of the long MX2 isoform. Such interference could
be due to two main effects: (1) the short isoform competes
with the long isoform for CA binding, or (2) overexpression of
the short isoform alters the oligomerization equilibrium between
the two MX2 isoforms, thereby perturbing antiviral activity. To
distinguish between these scenarios, we overexpressed
monomeric MX2 D1-25 bearing the M574D mutation (Buffone
Figure 3. The Short Isoform of MX2 Is a Domi-
nant Negative Regulator of the Long Isoform in
HIV-1-Infected Cells
(A) U87-MG CD4/CXCR4 cells were transduced with
EasiLV-expressing luciferase (Luc), MX2, MX2 D1-25,
or MX2 D1-25 M574D and treated with doxycycline for
24 h. At that time, half of the cells were treated with
500 U/ml IFNa for a further 24 h while the other half was
left untreated. Cells were then challenged with an HIV-
1-based lentiviral vector expressing GFP. After 2 days,
the percentage of GFP-expressing cells was evaluated
by flow cytometry (nR 3, mean ± SD). The fold-differ-
ence in infection in the presence of IFNa is indicated
(*p < 0.05, unpaired t test). See also Figure S1.
(B and C) As in (A), but using CTR CRISPR (B) or MX2
CRISPR (C) U87-MG CD4/CXCR4 cells (nR 3, mean ±
SD). The fold-difference in infection in the presence of
IFNa is indicated (*p < 0.05; ns, non-significant; un-
paired t test).
See also Figure S1.et al., 2015; Dicks et al., 2015), excluding any possibility of
interaction between both protein isoforms. Critically, the IFN-
imposed block was reduced to a similar extent as seen with
MX2 D1-25, indicating that competing for CA binding rather
than altered oligomerization underlies the interference with
MX2 activity.
To further characterize the inhibition of the IFN-imposed block
induced by the short isoform of MX2, we used an engineered
U87-MG CD4/CXCR4-derived cell line where the MX2 alleles
had been inactivated using CRISPR-Cas9 technology (Dicks
et al., 2018), as well as a control (CTR) CRISPR cell line. Impor-
tantly, the reductions in IFN-induced virus suppression seen
when MX2 D1-25 or MX2 D1-25 M574D are expressed were
only observed in the CTR CRISPR cells and not in MX2 CRISPR
cells, demonstrating that the endogenous MX2 protein is the
specific molecular target of this effect (Figures 3B and 3C; Fig-
ure S1 shows the corresponding immunoblot analyses of protein
expression level).
The G-domain-Capsid Interaction Enhances the
Antiviral Activity of MX2
In seeking to substantiate our model for MX2 isoforms
competing for capsid binding, we first returned to the CANC
interaction assay. More specifically, we used a competition
assay to focus on whether the G domain of MX2 affects binding
to CANC complexes in the context of mixed reactions where full-
length wild-type MX2 was also present. We therefore incubated
CANCs with extracts containing full-length MX2 bearing an HA
(hemagglutinin)-tag, plus either wild-type MX2, MX2 R11-13A,
MX2 (GMX1), or MX1 (NTDMX2), each carrying a FLAG-tag. Levels
of pelleted MX2-HA and FLAG-tagged proteins were compared
to measure how well each MX variant competes against wild-
typeMX2 for CANCbinding; MX2-FLAG served as the control re-
action, and all values for relative binding were compared to this
sample. As shown in Figure 4A, MX proteins that interact with
capsid via a single region—either the G domain (MX2 R11-13A)or the NTD (MX2 (GMX1) and MX1 (NTDMX2)—all competed for
CANC binding less effectively than wild-type MX2, with relative
binding only reaching 50%–60% of that of the wild-type pro-
tein. Importantly, these reductions in binding capacity were
similar in degree irrespective of whether theNTD or theG domain
was missing, highlighting the significant role played by both do-
mains in maximizing efficient capsid binding.
Though these results demonstrate the increased capsid asso-
ciation of wild-type MX2 compared to MX2 (GMX1), we have pre-
viously reported that this chimeric protein is as antiviral as wild-
type MX2 in single-cycle infection experiments (Goujon et al.,
2014). To gain further insight into this issue, we performed
spreading HIV-1 infection experiments in the presence of MX2,
MX2 (GMX1), or MX1 (as negative control) alone or together
with the short isoform of MX2. When alone, MX2 and MX2
(GMX1) sustained the same viral replication kinetics, at least
during the first 3 days of infection, followed by a slightly lower
viral production for MX2 (Figure 4B, left panel), consistent with
previous results (Goujon et al., 2014). Importantly, when co-ex-
pressed with MX2 (D1-25), MX2 displayed stronger antiviral
function thanMX2 (GMX1) (Figure 4B, right panel), thus confirming
the impaired antiviral capacity of MX2 containing the G domain
of MX1. In an independent validation, a similar phenotype was
also observed in single-cycle experiments where cells were
challenged with an HIV-1-based lentiviral vector (Figure S2A).
Corresponding immunoblot analyses of protein expression
levels are shown in Figure S3A.
We and others have demonstrated the importance of MX2
oligomerization for antiviral activity (Buffone et al., 2015; Dicks
et al., 2015; Alvarez et al., 2017). To rule out a role for oligomer-
ization in these results, we performed the same competition
experiments described in Figure 4B in the presence of the
monomeric short isoform MX2 D1-25 M574D. Results obtained
show how under these conditions, where no interaction between
the short isoform and wild-type/chimeric MX2 is possible, wild-
type MX2 again restricted HIV-1 more effectively than MX2Cell Reports 29, 1923–1933, November 12, 2019 1927
Figure 4. The G Domain of MX2 Enhances the Interaction with CANC Complexes and HIV-1 Inhibition
(A) Cell lysates from 293T cells expressing HA-tagged wild-type MX2 were mixed with cell lysates expressing FLAG-tagged wild-type MX2, MX2 R11-13A, MX2
(GMX1), or MX1 (NTDMX2). These were added to CANC assemblies, pelleted through a sucrose cushion, and the HA- and FLAG-tagged proteins present in input,
Sup, and pellet fractions were quantified by immunoblot and corrected for the amount of protein present in the input. The level of bound protein in each
competition experiment was normalized to the value obtained in theMX2-HA versusMX2-FLAG sample (n = 3, mean ±SD; *p < 0.05; ns, non-significant; unpaired
t test).
(legend continued on next page)
1928 Cell Reports 29, 1923–1933, November 12, 2019
(GMX1) (Figure 4C; Figure S3B shows the corresponding
immunoblot analyses). A similar phenotype was also obtained
in single-cycle experiments using an HIV-1 lentiviral vector
(Figure S2B).
The Interaction between the G Domain of MX2 and the
Capsid Is Complex
In order to map the region(s) of the G domain important for the
interaction with capsid, we created three chimeric MX2 DNTD
proteins where G-domain residues 92–234, 235–322, and 323–
387 (i.e., spanning the whole G domain) were swapped for their
complementary regions fromMX1 (MX2DNTD [92-234MX1], MX2
DNTD [235-322MX1], andMX2DNTD [323-387MX1], respectively).
None of these chimeric proteins were able to bind to CANC as-
semblies (Figure 5A), suggesting the involvement of all three re-
gions in the interaction.
Alignment of theG-domain sequences ofMX1 andMX2 shows
13 regions where the amino acid sequences differ (Figure 5B,
underlined residues). We therefore introduced each region
individually into MX2 DNTD and addressed their CANC-binding
ability. Interestingly, we found that three discrete regions are
necessary for CANC binding (residues 174–185, 257–266, and
334–352; highlighted in gray in Figures 5B and S4), while all other
mutant proteins maintained their ability to bind (Figure S5). Of
note, each of these three regions is located within one of the
extended regions analyzed in Figure 5A.
We then individually mutated all residues within these three
regions and found that amino acids G184, N260, and Q351 are
necessary for the G domain’s interaction with the capsid (Fig-
ure 5C; indicated in bold within each highlighted region in
Figure 5B). Finally, we introduced the G184S, N260S, and
Q351E mutations individually or in combination into full-length
MX2 and performed competition experiments against MX2
D1-25 during spreading HIV-1 replication. Cells expressing
wild-type MX2 sustained lower levels of viral replication than
seen with any of the mutants, particularly when compared to
the triple mutant G184S/N260S/Q351E (Figure 5D; Figure S6
shows the corresponding immunoblot analyses). In the
absence of MX2 D1-25, none of these mutants supported
higher viral replication when compared to wild-type MX2
(data not shown), as expected from prior results obtained un-
der the same conditions with MX2 (GMX1) (Figure S2A). These
results demonstrate that multiple residues within MX2’s G
domain contribute to capsid binding and confirm their impor-
tance for full antivirus function.
Oligomerization Increases the Avidity of the MX2-
Capsid Interaction
We and others have shown how MX2 dimerization, but not
higher-order oligomerization, is required for viral inhibition (Buf-(B) U87-MG CD4/CXCR4 cells were transduced with a lentiviral vector system co
alone or together with the EasiLV-expressing HA-tagged MX2 D1-25. Two days l
D1-25 induced with 0.5 mg/ml doxycycline. Cells were then infected with HIV-1
every 24 h. Infectivity of each collected sample was determined using HeLa-TZM
48 h (n = 4, mean ± SD). See also Figures S2A and S3.
(C) As in (B), but expressing HA-tagged monomeric mutant MX2 D1-25M574D tog
See also Figures S2B and S3.fone et al., 2015; Dicks et al., 2015), indicating that the mono-
meric protein lacks antiviral activity. Therefore, we introduced
the monomer-only mutations M574D and M527D into MX2
and MX1 (NTDMX2), respectively, and examined their ability to
bind to assembled CANC complexes (Figure 6A). In agreement
with previous work, dimerization or higher-order oligomeriza-
tion was not required for CANC interaction (Buffone et al.,
2015), although the levels of protein recovered in the pellet
fraction were visibly reduced. To quantify the contribution of
MX2 oligomerization to capsid binding, we then performed
in vitro competition experiments. We incubated CANC assem-
blies with FLAG-tagged MX2 M574D together with HA-tagged
wild-type MX1, MX2, or MX2 M574D, and the levels of pelleted
proteins were quantified. Inspection of the data shows that the
binding of MX2 M574D-FLAG to CANCs was most efficient in
the absence of competition (i.e., in the presence of MX1-HA).
Importantly, the binding of MX2 M574D-FLAG was reduced
more effectively in competition with wild-type MX2-HA,
compared to competition against MX2 M574D-HA (Figure 6B;
compare left and middle panels). This result demonstrates
the importance of protein oligomerization for increasing the
avidity of MX2-capsid binding.
DISCUSSION
The G domain of MX1 plays an important role in the inhibition of
different viruses, such as IAV and THOV (Pitossi et al., 1993;
Ponten et al., 1997). Similarly, it has recently been described
that the GTPase activity of MX2 is necessary for the inhibition
of a number of herpesviruses (Crameri et al., 2018; Schilling
et al., 2018). However, the role of the G domain of MX2 in the in-
hibition of HIV-1 has been less clear, particularly as mutant pro-
teins deficient for GTPase enzymatic activity maintain antiviral
activity (Goujon et al., 2013; Kane et al., 2013; Matreyek et al.,
2014).
In this work, we revisit the importance of theMX2G domain for
the control of HIV-1 infection. We show how, in addition to the
MX2-capsid interaction that is driven by the NTD,MX2 also inter-
acts with the capsid through its G domain. CANC-interaction ex-
periments using chimeric proteins demonstrate that transfer of
the G domain of MX2 to MX1 DNTD or GFP is sufficient to confer
CANC binding (Figure 2B), thus defining a second point of inter-
action in addition to that mediated by the MX2 NTD (Figure 1C).
In vitro competition experiments further support these findings
and demonstrate that the G domain enhances the interaction
between MX2 and the HIV-1 capsid lattice, a point that is illus-
trated by wild-type MX2 outcompeting MX2 (GMX1) for binding
to HIV-1 CANC complexes (Figure 4A). While the contributions
of G domains to MX-mediated viral suppression are well recog-
nized (Pitossi et al., 1993; Gao et al., 2010; Crameri et al., 2018;nferring puromycinR and expressing FLAG-tagged MX1, MX2, or MX2 (GMX1)
ater, transduced cells were selected with 1 mg/ml puromycin for 48 h and MX2
NL4-3 (185 ng p24
Gag), and culture supernatants were harvested and stored
bl indicator cells and measuring chemiluminescent b-galactosidase activity at
ether with MX1, MX2, or MX2 (GMX1), instead of MX2 D1-25 (n = 4, mean ± SD).
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Figure 5. Identification of Single Residues Important for the Capsid-G-Domain Interaction and the Antiviral Function of MX2
(A) Chimeric proteinsMX2DNTD (92-234MX1), MX2DNTD (235-322MX1), andMX2DNTD (323-387MX1) were expressed in 293T cells and lysatesmixed with CANC
assemblies, pelleted through a sucrose cushion. input, Sup, and pellet fractions were analyzed by immunoblot (n = 4).
(B) Sequence alignment of the G-domain regions of humanMX1 (red) andMX2 (blue) showing the consensus sequence between them (black). Underlined are the
13 regions of sequence difference, with the three regions found to be important for CANC binding highlighted and the three key residues shown in bold. See also
Figure S4.
(C) Residues found on the three different regions of the MX2 G domain important for CANC binding were individually mutated to their MX1 counterparts in a MX2
DNTD background and the proteins expressed in 293T cells. Lysates weremixedwith CANC assemblies, pelleted through a sucrose cushion, and input, Sup, and
pellet fractions were analyzed by immunoblot (nR 3). A representative immunoblot for CANC (a-CA) is shown. See also Figure S7.
(D) U87-MG CD4/CXCR4 cells doubly transduced with puromycinR lentiviral vectors expressing MX2, MX2 G184S, MX2 N260S, or MX2 Q351E together with
EasiLV-expressing MX2 D1-25 were selected with 1 mg/ml puromycin and treated with 0.5 mg/ml doxycycline to induce MX2 D1-25. Cells were infected with
HIV-1NL4-3 (350 ng p24
Gag), and culture supernatants were harvested every 24 h. Levels of infectivity for each sample were determined using HeLa-TZMbl in-
dicator cells (n = 4, mean ± SD).
See also Figure S6.
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Figure 6. Oligomerization of MX2 Increases
the Avidity for Capsid
(A) 293T cells were transfected with vectors ex-
pressing wild-type MX2 or monomeric mutants
MX2 M574D and MX1 (NTDMX2) M527D. Lysates
were mixed with CANC assemblies, pelleted
through a sucrose cushion, and input, Sup, and
pellet fractions were analyzed by immunoblot
(n R 3). A representative immunoblot for CANC
(a-CA) is shown.
(B) Cell lysate from 293T cells expressing FLAG-
tagged MX2 M574D was mixed with lysates ex-
pressing HA-tagged wild-type MX1, MX2, or MX2
M574D. Mixtures were added to CANC assem-
blies, pelleted through a sucrose cushion, and the
HA- and FLAG-tagged proteins present in the
input and pellet fractions quantified by immuno-
blot. The ability of each protein to bind to CANC
was calculated as the ratio between the band in-
tensities measured in pellet and input fractions.
Finally, their relative CANC binding activity was
determined by comparing the values with those
obtained for MX2 M574D-FLAG versus MX2
M574D-HA (n = 3, mean ±SD; *p < 0.05; unpaired t
test).Schilling et al., 2018), we now present evidence for a G domain
also acting through direct binding to a viral substrate, rather
than by catalyzing GTP hydrolysis.
Working from this, wehave shown that the short isoformofMX2
(MX2 D1-25), by virtue of its intact G domain, can therefore
interact with the capsid. Though it lacks antiviral function (Goujon
et al., 2013; Kane et al., 2013; Fricke et al., 2014; Matreyek et al.,
2014), this result prompted us to revisit the functionality of MX2
D1-25 during the IFN-induced inhibition of HIV-1 infection (when
this form is naturally expressed; Goujon et al., 2013; Kane et al.,
2013). Importantly, we found that MX2 D1-25 is an effective sup-
pressor of the IFN response (Figure 3) and that the endogenous
MX2 protein is the target for this phenotype, with competition
for CA binding being the underpinning mechanism driving this ef-
fect. Consistent with the G domain contributing to CA binding, the
short isoform of MX2 is a stronger competitor against MX2 (GMX1)
than against wild-type MX2 (Figure 4B). These results point to the
short isoform of MX2 playing a biological role during virus infec-
tion and invoke a scenario where IFN-stimulated cells can limitCell Reportsthe activity of full-length MX2. Though
the basis for the regulatory circuit is not
yet known, we speculate that full-length
MX2 exerts deleterious effects on cell
function, such as impeded nuclear trans-
port (Kane et al., 2018), that need to be
minimized. In this regard, it is interesting
that a number of ISGs express shorter
protein isoforms that, at least in the case
of mitochondrial antiviral-signaling
(MAVS) protein, can exert a checkpoint-
like function that dampens the activity of
their full-length counterparts (Brubaker
et al., 2014).Structural data highlight the role played by the G domain in the
oligomerization of both MX1 and MX2 (Gao et al., 2010, 2011; Al-
varez et al., 2017). Therefore, it could be argued that different olig-
omerization kinetics betweenMX2D1-25 andMX2 orMX2 (GMX1)
could be affecting the antiviral activity of the proteins. Neverthe-
less, in infection experiments carried out in the presence of the
monomeric variantMX2D1-25M574D (Buffone et al., 2015; Dicks
et al., 2015), where interactions between different MX2 species
are prevented, wild-type MX2 still shows a more potent inhibition
of HIV-1 than does MX2 (GMX1) (Figure 4C). This finding is in good
agreement with results obtained by overexpression of the same
monomeric short isoform in the presence of IFNa, pointing to
competition for CA binding as the mechanistic basis for downre-
gulation of the full-length protein.
Detailed mapping of G-domain residues involved in capsid
binding identified three amino acids as being important: glycine-
184, asparagine-260, and glutamine-351 (Figure 5C). Infection ex-
periments performed in the presence of competing MX2 D1-25
showed that the combined triple-mutant G184S/N260S/Q351E29, 1923–1933, November 12, 2019 1931
has theweakest antiviral phenotype, with each singlemutant hav-
ing effects that scored as intermediate (Figure 5D). Interestingly,
these three residues are located at distance from each other and
arepositionedwithindifferentsurfacesof theGdomain (FigureS7).
The basis for the effects of thesemutations on capsid interactions
remains to be determined and may involve direct binding and/or
conformational changes. Obtaining high-resolution structural in-
formation on the complex betweenMX2 and the HIV-1 capsid lat-
tice will help answer such questions.
Our description of the MX2 G-domain-capsid interaction is
concordant with the conclusions of a recent study showing that
higher-order MX2 tubular structures expose their G domains to-
ward the outer surface (Alvarez et al., 2017), possibly allowing in-
teractionswith incoming viral capsids.We can envisage a number
of benefits for MX2 containing two CA-binding sites. First,
improved capsid binding and enhanced antiviral efficacy may
be particularly important during the initial phases of an IFN-
induced antiviral response, as ISGs have yet to reach optimal
expression levels. Second, the MX2 G-domain-capsid interaction
allows fine-tuning of full-length MX2 activity by its short isoform,
possibly limiting any deleterious effect that the long isoform
may have on cellular functions. Third, MX2 interacts with other
cellular factors, notably nucleoporins (Dicks et al., 2018; Kane
et al., 2018), as part of the antiviral process; this interaction also
requires the NTD of MX2 such that additional CA-binding sites
within MX2 may facilitate simultaneous contact with different
ligands, a property that is likely amplified byMX2 oligomerization.
In sum, we propose that the interaction of the G domain of MX2
with the capsid not only improves HIV-1 recognition, but may
also be required for the precise control of antiviral activity.
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Antibodies
Goat polyclonal anti-MX2 N17 Santa Cruz Biotechnologies Cat#sc-47197; RRID:AB_2147726
Mouse anti-goat-HRP (horse radish peroxidase) Santa Cruz Biotechnologies Cat#sc-2354; RRID:AB_628490
Mouse monoclonal anti-Flag-HRP M2 Sigma Cat#F3165-1MG; RRID:AB_259529
Rat monoclonal anti-HA-HRP 3F10 Sigma Cat#12 013 819 001; RRID:AB_390917
Mouse monoclonal anti-CA 24.2 Fouchier et al., 1997 N/A
Mouse monoclonal anti-tubulin Sigma Cat#T5168-.2ML; RRID:AB_477579
Goat monoclonal anti-mouse IRDye fluorescent Li-Cor Biosciences Cat#926-32210; RRID:AB_621842
Rabbit polyclonal anti-MX1 Abcam Cat#ab95926; RRID:AB_10677452
Bacterial and Virus Strains
HIV-1IIIB Hwang et al., 1991 N/A
HIV-1NL4.3 Adachi et al., 1986 N/A
Escherichia coli Rosetta (DE3) Merck Millipore Cat#70954
Chemicals, Peptides, and Recombinant Proteins
Isopropyl b-D-1-thiogalactopyranoside (IPTG) ThermoFisher Scientific Cat#R0393
Ammonium sulfate Sigma Cat#A4418-1KG
Poly(ethyleneimine) solution Fluka Analytical Cat#3880-100ML
MES hydrate Sigma Cat#M8250-250G
Dithiothreitol (DTT) ThermoFisher Scientific Cat#20290
Sodium chloride VWR Chemicals Cat#27810.364
Phenylmethanesulfonyl fluoride Sigma Cat#P7626-1G
Tris Base Fisher Scientific Cat#BP152-5
Potassium chloride Sigma Cat#P9541-1KG
Sucrose Sigma Cat#S0398-1KG
HiTrap SP HP columns Ge Healthcare Life Sciences Cat#17115201
cOmplete Mini protease inhibitor cocktail tablets Sigma Cat#11836153001
Glycerol Sigma Cat#G5516-1L
DMEM, high glucose, GlutaMAX Supplement ThermoFisher Scientific Cat# 10566016
Fetal Bovine Serum ThermoFisher Scientific Cat#10270
Penicillin Streptomycin (Pen Strep) ThermoFisher Scientific Cat#15140-122
EcoRI-HF New England Biolabs Cat#R3101S
NotI-HF New England Biolabs Cat#R3189S
XhoI New England Biolabs Cat#R0146L
BamHI New England Biolabs Cat#R)136M
Puromycin ThermoFisher Scientific Cat#A1113802




HIV-1 p24 antigen ELISA kit PerkinElmer Cat#NEK050001KT
Tropix Galacto-Star kit ThermoFisher Scientific Cat#T1014
Deposited Data
PDB file Fribourgh et al., 2014 4WHJ
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
HeLa-TZMbl NIH AIDS Reagent Program Cat#8129
293T ATCC Cat#CRL-3216






pST39 Tan, 2001 N/A
pCAGGs Goujon et al., 2014 N/A
EasiLV-MCS Goujon et al., 2013 N/A
PuromycinR Goujon et al., 2013 N/A
Software and Algorithms
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
GraphPad Prism version 6.0.0 GraphPad Software https://www.graphpad.comLEAD CONTACT AND MATERIALS AVAILABILITY
For further information and requests for reagents, please contact the Lead Contact, Michael H. Malim (michael.malim@kcl.ac.uk).
The plasmids generated in this study are available upon request without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
Control CRISPR U87-MG cells and MX2 CRISPR U87-MG cells have been described before (Dicks et al., 2018). The CRISPR modi-
fied cells, U87-MG CD4/CXCR4 cells (Goujon et al., 2013), HeLa-TZMbl indicator cells (NIH AIDS Reagent Program) and 293T cells
were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with heat-inactivated fetal bovine serum (10%), L-gluta-
mine, penicillin (100 U/ml) and streptomycin (100 mg/ml).
HIV-1 and lentiviral vector infections
Wild-type HIV-1NL4-3 (Adachi et al., 1986) stocks were obtained by filtration of culture medium from transfected 293T cells, and
p24Gag content determined by ELISA according to the manufacturer’s instructions (Perkin-Elmer). U87-MG CD4/CXCR4 cells
were transduced with either puromycinR encoding Flag-tagged MX2, MX1, MX2 (GMX1), MX2 G184S, MX2 N260S, MX2 Q351E or
MX2 G184S/N260S/Q351E alone, or together with EasiLV encoding HA-tagged MX2 D1-25 or MX2 D1-25 M574D. After selection
for puromycin resistant cells for 48 h, 2.5x104 cells were seeded in a 24 well plate, challenged with HIV-1NL4-3 (corresponding to
185 ng p24Gag for experiments comparing MX1, MX2 and MX2 (GMX1); or 350 ng p24
Gag for experiments comparing wild-type
MX2 and mutants) and the medium replaced after 6 h. For every subsequent 24 h period, for a total of 120 h, medium was filtered
and stored at 80C. To quantify released infectious virus at each time point, HeLa-TZMbl indicator cells (NIH AIDS Reagent Pro-
gram) were challenged and productive infection determined at 48 h by measuring chemiluminescent b-galactosidase activity using
the Tropix Galacto-Star system according to the manufacturer’s instructions (Applied Biosystems).
HIV-1 based lentiviral particles expressing GFP (HIV-1/GFP) were produced as described previously (Goujon et al., 2013). Infec-
tivity experiments using EasiLV and/or puromycinR transduced U87-MG CD4/CXCR4 cultures were carried out as previously
described, with the percent of cells expressing GFP enumerated by flow cytometry (FACSCanto II; BD Biosciences) at 48 h post
infection (Dicks et al., 2015). For experiments where U87-MG CD4/CXCR4 cells were treated with IFNa, cells were transduced
with EasiLV vectors expressing either luciferase, MX2, MX2 D1-25 or MX2 D1-25 M574D and the medium replaced 6 h later for fresh
DMEMcontaining 0.5 mg/ml doxycycline. 24 h later, 500 U/ml of IFNa-2b (INTRONA,Merck, Sharpe &DohmeCorp.) was added, and
after a further 24 h the cells were challenged with HIV-1/GFP. After 48 h, productive infection was monitored by flow cytometry.
METHOD DETAILS
Protein expression and purification
DNA encoding HIV-1IIIB (Hwang et al., 1991) Capsid-Nucleocapsid (CANC, corresponding to Gag residues 133-432) was PCR ampli-
fied and inserted into pST39 (Tan, 2001) using the NdeI and BamHI sites. Protein was expressed in Escherichia coli Rosetta (DE3)Cell Reports 29, 1923–1933.e1–e3, November 12, 2019 e2
cells (Merck Millipore) as previously described (Schaller et al., 2017). Briefly, CANC expression was induced with 1 mM of isopropyl
b-D-thiogalactopyranoside (IPTG) for 6 h at 30C. Cells were collected by centrifugation and lysed by sonication. Cell debris were
removed by centrifugation at 30000 g for 20 min. Nucleic acids present in the supernatant were removed by adding of 0.11 volumes
of 2 M ammonium sulfate and the same volume of 10% polyethylenimine (PEI) pH 8.0. CANC was precipitated from the supernatant
by adding 0.35 volumes of saturated ammonium sulfate and centrifugation at 10000 g for 15min. Pelleted protein was resuspended in
50 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT, 0.5 M NaCl, 10% glycerol, 1 mM PMSF and then diluted with the same buffer lacking
NaCl to a final concentration of 0.2 M NaCl. This was cleared by centrifugation and CANC polished by cation-exchange chromatog-
raphy on a 5 mL HiTrap SP HP column (GE Healthcare) using 50mMMES pH 6.5, 1 mMEDTA, 1 mMDTT, 0.2 MNaCl, 10% glycerol,
1 mMPMSF as the equilibration buffer. CANCwas eluted following a linear gradient resulting frommixing the equilibration buffer with
the same buffer adjusted to 1 M NaCl. Protein-enriched fractions were pooled and CANC was precipitated by adding one volume of
saturated ammonium sulfate. Finally, resulting CANC was resuspended at 200 mM in 30 mM MES pH 6, 1 mM EDTA, 0.5 M NaCl,
10 mM DTT, and stored at 80C.
In vitro assembly of CANC complexes
Assembled CANC complexes were obtained by diluting the purified protein to 40 mM in 50mMTris-HCl pH 8, 100mMNaCl with 5 mM
TG50 oligonucleotide and overnight incubation at room temperature. The sequence of TG50 is: 50-25(TG)-30
CANC pull-down
293T cells transfected with vectors expressing hemagglutinin (HA)- or Flag-tagged proteins were harvested and resuspended in hy-
potonic lysis buffer (10 mM Tris-HCl pH 8, 10 mM KCl, 1x protease inhibitor cocktail [Roche]) and lysed using a Dounce homogene-
izer. Lysates were cleared by centrifugation at 20000 g at 4C for 15 min. In pull-down experiments, 200 mL of cell lysates were mixed
with 40 mL of 40 mM assembled CANC (an input sample was reserved from this mix) or 40 mL of Capsid assembly buffer (Cab, 50 mM
Tris-HCl pH 8, 100 mM NaCl) containing 5 mM TG50 and incubated under gently agitation at room temperature for 1 h. In the case of
competition experiments, 200 ml of cell lysate expressing HA-tagged proteins and 200 ml of cell lysate expressing Flag-tagged pro-
teins were mixed with 80 mL of 40 mM assembled CANC. The mixture was then overlaid onto a 250 mL sucrose cushion (70%weight/
volume) and centrifuged at 20000 g at room temperature for 10 min. A sample of the supernatant was withdrawn for further analysis.
The pellet was washedwith 500 mLwash buffer (50mMTris-HCl pH 8, 50mMNaCl, 5mMKCl), and re-centrifuged at 10000 g at room
temperature for 8 min. Finally, the pellet was resuspended in 50 mL of 1x SDS-PAGE loading buffer. Input, supernatant and pellet
fractions were analyzed by immunoblot using anti-MX2 goat polyclonal antibody (N17, Santa Cruz Biotechnology) and mouse
anti-goat horseradish peroxidase (HRP)-conjugated monoclonal antibody (Santa Cruz), anti-Flag HRP-conjugated mouse mono-
clonal M2 (Sigma), anti-HA HRP-conjugated rat monoclonal antibody (Sigma), anti-CA mouse monoclonal 24.2 (Fouchier et al.,
1997) or anti-tubulin mouse monoclonal (Sigma) together with goat anti-mouse IRDye fluorescent monoclonal antibody (Li-Cor Bio-
sciences) and detected using a LI-COR Odyssey FC imaging system (LI-COR Biosciences).
Plasmid constructs
pCAGGs plasmid (Adgene) was used for the expression of cDNA fragments used in transfection experiments, after PCR amplification
and inclusion of either Flag- or HA-tags, using EcoRI-XhoI or NotI-XhoI sites. Fragments encoding the chimeric proteins GFP
(NTDMX2), GFP (GMX2), MX2 DNTD (92-234MX1), MX2 DNTD (235-322MX1) or MX2 DNTD (323-387MX1) were produced by standard
overlapping PCR. Truncated fragments encoding MX2 DNTD, MX1 (NTDMX2) or GFP (NTDMX2) were obtained from full-length ver-
sions (Goujon et al., 2014) using PCR. Site-directed mutagenesis was used to obtain single or multiply mutated constructs, using
PCR amplification methods. Where required, DNA constructs were cloned into the doxycycline-inducible lentiviral vector EasiLV-
MCS (Goujon et al., 2013) or into a lentiviral vector expressing a CD4-IRES-puromycin N-acetyltransferase expression cassette
(puromycinR) (Goujon et al., 2013) using BamHI-XhoI restriction sites.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc.). For each experiment, mean ± SD was
calculated and the unpaired t test was applied in all cases, considering p < 0.05 as the level of statistical significance. Corresponding
results from statistical analyses performed can be found in the relevant figure legends.
DATA AND CODE AVAILABILITY
This study did not generate any unique datasets or code.e3 Cell Reports 29, 1923–1933.e1–e3, November 12, 2019
